Sponsored Content
Intercell: Restructuring Is Progressing
Sponsored Content
Sales of the company’s only product on the market increased by 85% in the first six months of the year. Net loss was down 44.2%.

The listed vaccine producer Intercell on Tuesday presented results for the second quarter and the first half of 2011. Revenue increased by 27.5% to € 18.38m from January to June. Net loss was reduced by 44.2% and amounted to € 12.9m which is still 70% of revenue.
Sales of the company’s only product currently on the market, a vaccine to prevent Japanese Encephalitis…
or Log In
Sponsored Content
Sponsored Content
Sponsored Content
Sponsored Content
Fast News Search
Related News
Intercell Is Looking for Financial Investors (July 19, 2011)
Intercell: “We Will Stabilize Our Share Price” (June 21, 2011)
Intercell to Cut Jobs and Research Budget (June 8, 2011)
Intercell: Sale Is No Longer Ruled Out (May 10, 2011)
Lingelbach New CEO for Intercell (May 5, 2011)
Sponsored Content
Read More
Featured
Sponsored Content